How can hypotension causing inability to undergo dialysis be managed in patients with end-stage renal disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Management of Hypotension Preventing Dialysis in ESRD Patients

The most critical intervention for hypotension preventing dialysis is to increase dialysis treatment time, which allows for slower ultrafiltration rates and better hemodynamic tolerance 1.

Primary Dialysis Prescription Modifications

The foundation of managing intradialytic hypotension centers on reducing ultrafiltration (UF) rates through two main strategies:

Increase Dialysis Time

  • Lengthen individual treatment sessions beyond the bare minimum of 3 hours 2
  • Add additional dialysis sessions per week (more frequent dialysis)
  • Consider transition to home nocturnal hemodialysis (6-8 hours, 3-6 nights/week) for severe cases 2
  • The KDIGO 2020 guidelines specifically emphasize that chronically hypotensive patients particularly benefit from increased dialysis time 1

Reduce Interdialytic Weight Gain (IDWG)

  • Implement strict dietary sodium restriction to minimize fluid accumulation between sessions 2
  • Lower IDWG directly reduces the volume that must be removed per session, allowing gentler UF rates
  • Target UF rates should be individualized but kept as low as feasible 1

Modality Considerations

For patients with persistent chronic hypotension refractory to HD modifications, consider switching to peritoneal dialysis (PD), as these patients may tolerate PD better than HD 1. However, evidence confirming superior outcomes after modality transition remains limited.

PD-Specific Hypotension Management

If already on PD, address hypotension by 1:

  • Reducing UF volume by adjusting solutions (use less hypertonic glucose or switch icodextrin to conventional 1.5% glucose)
  • Omitting day dwell (in APD) or night dwell (in CAPD) if significant residual kidney function exists
  • Withholding antihypertensive medications
  • Liberalizing salt intake (contrary to HD management)

Pharmacological Interventions

Midodrine: Mixed Evidence

The evidence for midodrine is contradictory and concerning:

  • Short-term studies show benefit: Meta-analysis demonstrated nadir systolic BP improved by 13 mm Hg with symptom improvement 1. A 1997 study showed significant improvements in intradialytic BP (96.6 to 114.7 mm Hg systolic) with good symptom relief 3

  • However, observational data raises serious safety concerns: When midodrine users were matched to non-users by peridialytic BP levels, midodrine use was associated with significantly higher risks of cardiovascular events, all-cause hospitalization, and mortality 1

Given the mortality signal in observational data, midodrine should be reserved only for refractory cases after optimizing dialysis prescription, and used with extreme caution.

Antihypertensive Medication Review

  • Immediately review and discontinue or reduce antihypertensive medications in hypotensive patients 1
  • This is often overlooked but critical

Experimental: Vasopressin

Vasopressin administration shows promise in research settings, as many HD patients with recurrent hypotension fail to increase vasopressin release appropriately 4. However, this remains investigational and is not standard practice.

Technical Dialysis Adjustments

Dialysate Temperature

  • Use cooled dialysate to improve vascular stability 5

Dialysate Sodium

  • The optimal dialysate sodium concentration remains uncertain and controversial 1
  • Lower dialysate sodium reduces IDWG and BP but paradoxically increases intradialytic hypotension risk 1
  • Avoid aggressive sodium manipulation without careful monitoring

Alternative HD Modalities

Recent evidence suggests intermittent hemodialysis filtration mode (IHDF) reduces intradialytic hypotension incidence compared to conventional HD 6, though this requires specialized equipment.

Nutritional and Volume Assessment

Preserve Residual Kidney Function

  • Use loop diuretics if any residual urine output exists - observational data shows continuation of loop diuretics after HD initiation associates with lower IDWG and lower intradialytic hypotension rates 1
  • Consider RAS blockers (ACE inhibitors/ARBs) which may preserve residual kidney function, especially in PD patients 1

Nutritional Support

  • Ensure adequate protein and caloric intake
  • Monitor albumin, prealbumin, and hemoglobin levels 6
  • Protein-energy wasting exacerbates hypotension

Emerging Technologies

Bio-impedance spectroscopy and artificial intelligence for real-time risk prediction show promise for preventing hypotension episodes 5, though these are not yet widely available.

Critical Pitfalls to Avoid

  1. Do not reflexively prescribe midodrine without first optimizing dialysis prescription - the mortality signal cannot be ignored 1
  2. Do not maintain aggressive UF targets in chronically hypotensive patients - slower is safer
  3. Do not overlook medication reconciliation - antihypertensives prescribed for pre-ESRD hypertension often become inappropriate
  4. Do not ignore residual kidney function - preserving even minimal urine output significantly aids volume management 1
  5. Do not dismiss PD as an option - modality switch may be curative for refractory cases 1

Rare but Important: High-Output Heart Failure

In refractory cases, consider high-output heart failure from arteriovenous fistula with excessive flow (>2 L/min). Case reports demonstrate that AVF ligation can immediately cure refractory hypotension in appropriate clinical settings 7. This should be suspected when:

  • Hypotension persists despite all interventions
  • Evidence of volume overload with hypotension
  • High AVF flow rates on duplex ultrasound
  • Signs of right heart failure

Algorithmic Approach

Step 1: Increase dialysis time (first-line, most effective) 1, 2
Step 2: Reduce IDWG through sodium restriction 2
Step 3: Discontinue/reduce antihypertensive medications 1
Step 4: Use cooled dialysate 5
Step 5: Preserve residual function with diuretics if applicable 1
Step 6: Consider PD transition for refractory cases 1
Step 7: Midodrine only as last resort with informed consent about risks 1
Step 8: Evaluate for AVF-related high-output failure in truly refractory cases 7

The evidence strongly supports that dialysis prescription modification, not pharmacotherapy, should be the primary intervention for hypotension preventing dialysis tolerance.

References

2
Guideline

kdoqi clinical practice guideline for hemodialysis adequacy: 2015 update.

American Journal of Kidney Diseases, 2015

3
Research

Intradialytic hypotension: is midodrine beneficial in symptomatic hemodialysis patients?

American journal of kidney diseases : the official journal of the National Kidney Foundation, 1997

4
Research

Vasopressin and prevention of hypotension during hemodialysis.

Iranian Red Crescent medical journal, 2014

6
Research

Effect of intermittent hemodialysis filtration mode on intradialytic hypotension and nutritional status in patients with end-stage renal disease.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2025

Related Questions

In an adult with end‑stage renal disease on high‑efficiency hemodiafiltration (HDF) five times per week, who is non‑diabetic, has severe chronic hypotension, and a prior renal allograft loss, how should neurogenic hypotension be evaluated?
In a hemodialysis patient with ongoing symptomatic hypotension (systolic blood pressure 70–100 mm Hg) responsive to midodrine and recent 8‑lb weight loss, how should midodrine dosing, ultrafiltration volume, dry weight, and pre‑dialysis fluid intake be adjusted, and what follow‑up is recommended?
Can midodrine cause issues in patients with End-Stage Renal Disease (ESRD)?
Does midodrine affect kidney function?
Can a patient with End-Stage Renal Disease (ESRD) and refractory hypotension, who is already on steroids and midodrine, use Florinef (fludrocortisone) to manage their hypotension?
In a patient presenting with weakness, does hyperkalemia cause muscle pain, or is muscle pain a sign of hypocalcemia?
Do doxycycline and sulfasalazine cause black stool?
Can norepinephrine be administered in a 10% dextrose (D10) solution?
In an elderly patient two days after hip surgery who received D5W (hypotonic fluids) and now presents with confusion, serum sodium 121 mmol/L, serum osmolality ~250 mOsm/kg, urine osmolality 600 mOsm/kg, and urine sodium 46 mmol/L, what is the appropriate management: fluid restriction with monitoring, isotonic saline with furosemide, or hypertonic 3% saline?
Can obstructive sleep apnea (OSA) cause headaches?
How can bleeding from hemorrhoids be stopped while awaiting a gastroenterology appointment in a patient with atrial fibrillation on flecainide and not taking anticoagulants or antiplatelet agents?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.